Education
About Us
Working with TipRanks
Follow Us
Sol-Gel Technologies (SLGL)
NASDAQ:SLGL
SLGL Stock Chart & Stats
$43.17
-$0.16(-11.43%)
At close: 4:00 PM EST
$43.17
-$0.16(-11.43%)
Day’s Range― - ―
52-Week Range$4.01 - $52.26
Previous CloseN/A
Volume503.92K
Average Volume (3M)16.66K
Market Cap
$117.45M
Enterprise Value$61.45M
Total Cash (Recent Filing)$30.47M
Total Debt (Recent Filing)$1.39M
Price to Earnings (P/E)―
Beta1.58
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding2,785,787
10 Day Avg. Volume26,975
30 Day Avg. Volume16,656
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)8.98
Price to Sales (P/S)22.45
P/FCF Ratio-18.65
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue9.37
Enterprise Value/Gross Profit-6.10
Enterprise Value/Ebitda-3.74
Forecast
1Y Price Target
$50.00Price Target Upside15.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentSGT-610 pivotal trial is considered Sol-Gel's main value driver and is expected to generate significant revenue if approved.
Market ExpansionSol-Gel is eligible to receive up to $11M in combined potential upfront, regulatory and sales milestone payments for Twyneo and Epsolay in Canada.
Revenue ProjectionsSGT-610 is targeting potential peak revenue exceeding $300M annually with anticipated annual sales of over $270M by 2035.
Bears Say
Clinical Trial DelaysResults from the proof-of-concept trial are expected in late 2025 vs. prior guidance due to slower-than-anticipated patient enrollment.
Program DiscontinuationThe SGT-210 program in Darier disease has been discontinued following negative results from a clinical study.
Regulatory RisksRisks for the company include the failure of the pivotal trial of SGT-610 in Gorlin syndrome and inability to secure regulatory approval.
Sol-Gel Technologies News
SLGL FAQ
What was Sol-Gel Technologies’s price range in the past 12 months?
Sol-Gel Technologies lowest stock price was $4.01 and its highest was $52.26 in the past 12 months.
What is Sol-Gel Technologies’s market cap?
Sol-Gel Technologies’s market cap is $117.45M.
When is Sol-Gel Technologies’s upcoming earnings report date?
Sol-Gel Technologies’s upcoming earnings report date is May 08, 2026 which is in 134 days.
How were Sol-Gel Technologies’s earnings last quarter?
Sol-Gel Technologies released its earnings results on Nov 06, 2025. The company reported -$2.13 earnings per share for the quarter, missing the consensus estimate of -$2.09 by -$0.04.
Is Sol-Gel Technologies overvalued?
According to Wall Street analysts Sol-Gel Technologies’s price is currently Undervalued.
Does Sol-Gel Technologies pay dividends?
Sol-Gel Technologies does not currently pay dividends.
What is Sol-Gel Technologies’s EPS estimate?
Sol-Gel Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sol-Gel Technologies have?
Sol-Gel Technologies has 2,785,787 shares outstanding.
What happened to Sol-Gel Technologies’s price movement after its last earnings report?
Sol-Gel Technologies reported an EPS of -$2.13 in its last earnings report, missing expectations of -$2.09. Following the earnings report the stock price went down -2.141%.
Which hedge fund is a major shareholder of Sol-Gel Technologies?
Currently, no hedge funds are holding shares in SLGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sol-Gel Technologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$50.00 (15.82% Upside)
$50.00 (15.82% Upside)
Insider Transactions
Bought Shares
Worth $646.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 26.2%
Last 30 Days ▲ 26.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
682.16%
12-Months-Change
Fundamentals
Return on Equity
-29.59%
Trailing 12-Months
Asset Growth
-19.52%
Trailing 12-Months
Company Description
Sol-Gel Technologies
Sol-Gel Technologies (SLGL) is a clinical-stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. The company uses its proprietary sol-gel technology platform to create innovative topical drug delivery systems. Sol-Gel Technologies primarily targets skin diseases such as acne and rosacea, leveraging its expertise to formulate and advance products through clinical trials towards regulatory approval.
SLGL Stock 12 Month Forecast
Average Price Target
$50.00
▲(15.82% Upside)
Technical Analysis
Insight Molecular Diagnostics
―
Ovid Therapeutics
―
Shattuck Labs
―
Surrozen
―
Metagenomi, Inc.
―
Ownership Overview
13.80% Insiders
0.05% Mutual Funds
11.76% Other Institutional Investors
74.39% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---